Amedeo Smart

Free Medical Literature Service



Hepatitis C

  Free Subscription

Articles published in
    August 2021
  1. HLADY RA, Zhao X, El Khoury LY, Luna A, et al
    Interferon drives hepatitis C virus scarring of the epigenome and creates targetable vulnerabilities following viral clearance.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32111.
    >> Share

    July 2021
  2. SULKOWSKI MS, Moon J, Sherman K, Morelli G, et al
    A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: THE PRIORITIZE STUDY.
    Hepatology. 2021 Jul 13. doi: 10.1002/hep.32053.
    >> Share

  3. KIM OK, Nam DE, Hahn YS
    The Panx1/P2X4 pathway controls the secretion of miRNA-containing exosomes by HCV-infected hepatocytes.
    Hepatology. 2021 Jul 4. doi: 10.1002/hep.32042.
    >> Share

    June 2021
  4. NGUYEN LN, Nguyen LNT, Zhao J, Schank M, et al
    Immune activation induces telomeric DNA damage and promotes short-lived effector T cell differentiation in chronic HCV infection.
    Hepatology. 2021 Jun 10. doi: 10.1002/hep.32008.
    >> Share

  5. LIM AG, Stone J, Hajarizadeh B, Byrne M, et al
    Evaluating the prevention benefit of HCV treatment: Modelling the SToP-C treatment as prevention study in prisons.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32002.
    >> Share

    May 2021
  6. MESZAROS M, Truchi R, Ouzan D, Tran A, et al
    Sofosbuvir, glecaprevir, pibrentasvir, and ribavirin as a rescue therapy in difficult-to-treat hepatitis C patients.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31909.
    >> Share

  7. CLIPMAN SJ, Mehta SH, Rodgers MA, Duggal P, et al
    Spatiotemporal phylodynamics of hepatitis C among people who inject drugs in India.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31912.
    >> Share

    April 2021
  8. JONAS MM, Rhee S, Kelly DA, Del Valle-Segarra A, et al
    Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic hepatitis C virus: part 2 of the DORA study.
    Hepatology. 2021 Apr 2. doi: 10.1002/hep.31841.
    >> Share

    March 2021
  9. GHANY MG, Lok ASF, Dienstag JL, Feinstone SM, et al
    The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence.
    Hepatology. 2021 Mar 30. doi: 10.1002/hep.31830.
    >> Share

  10. JHAVERI R, Yee LM, Antala S, Murphy M, et al
    Responsible Inclusion of Pregnant Individuals in Eradicating Hepatitis C Virus.
    Hepatology. 2021 Mar 20. doi: 10.1002/hep.31825.
    >> Share

  11. GRAGNANI L, Lorini S, Marri S, Basile U, et al
    Haematological and genetic markers in the rational approach to HCV SVR patients with or without persisting cryoglobulinemic vasculitis.
    Hepatology. 2021 Mar 15. doi: 10.1002/hep.31804.
    >> Share

  12. PONZIANI FR, Gasbarrini A, Pompili M
    Letter to the Editor. Restructuring the Gut Microbiota of Cirrhotic Patients after HCV Eradication: a Matter of Time?
    Hepatology. 2021 Mar 5. doi: 10.1002/hep.31784.
    >> Share

  13. COCHARD J, Bull-Maurer A, Tauber C, Burlaud-Gaillard J, et al
    Differentiated cells in prolonged hypoxia produce highly infectious native-like hepatitis C virus particles.
    Hepatology. 2021 Mar 4. doi: 10.1002/hep.31788.
    >> Share

    February 2021
  14. HALL EW, Schillie S, Vaughan AS, Jones J, et al
    County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31756.
    >> Share

  15. ANTUORI A, Montoya V, Pineyro D, Sumoy L, et al
    Characterization of acute HCV infection and transmission networks in people who currently inject drugs in Catalonia: usefulness of dried blood spots.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31757.
    >> Share

  16. PARK H, Jiang X, Song HJ, Lo Re V 3rd, et al
    The Impact of Direct-acting Antiviral Therapy on End Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders.
    Hepatology. 2021 Feb 5. doi: 10.1002/hep.31732.
    >> Share

  17. CHEMIN I, Pujol FH, Scholtes C, Loureiro CL, et al
    Preliminary Evidence for Hepatitis Delta Virus Exposure in Patients Who Are Apparently Not Infected With Hepatitis B Virus.
    Hepatology. 2021;73:861-864.
    >> Share

    January 2021
  18. WELLHONER F, Doscher N, Woelfl F, Vital M, et al
    Eradication of chronic HCV infection: improvement of dysbiosis only in patients without liver cirrhosis.
    Hepatology. 2021 Jan 7. doi: 10.1002/hep.31700.
    >> Share

    November 2020
  19. KHATUN M, Sur S, Steele R, Ray R, et al
    Inhibition of long noncoding RNA Linc-Pint by hepatitis C virus in infected hepatocytes enhances lipogenesis.
    Hepatology. 2020 Nov 24. doi: 10.1002/hep.31656.
    >> Share

  20. SETIAWAN VW, Rosen HR
    Stratification of residual risk of hepatocellular carcinoma following HCV clearance with DAA in patients with advanced fibrosis and cirrhosis.
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31639.
    >> Share

    October 2020
  21. ALONSO S, Manzano ML, Gea F, Gutierrez ML, et al
    A model based on non-invasive markers predicts very low hepatocellular carcinoma risk after viral response in HCV-advanced fibrosis.
    Hepatology. 2020 Oct 6. doi: 10.1002/hep.31588.
    >> Share

    September 2020
  22. TERRAULT NA, Burton J, Ghobrial M, Verna E, et al
    Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors.
    Hepatology. 2020 Sep 14. doi: 10.1002/hep.31551.
    >> Share

    August 2020
  23. DEGASPERI E, Galmozzi E, Pelusi S, D'Ambrosio R, et al
    Hepatic fat - genetic risk score predicts hepatocellular carcinoma in HCV cirrhotic patients treated with DAAs.
    Hepatology. 2020 Aug 6. doi: 10.1002/hep.31500.
    >> Share

  24. KAPILA N, Rahman AU, Zervos XB
    Hepatology. 2020;72:788.
    >> Share

  25. TERRAULT NA, Feld JJ
    Letter to the Editor: Safety First: Favoring Prophylactic/Preemptive Over Delayed Treatment in D+/R- Transplants.
    Hepatology. 2020;72:787.
    >> Share

    July 2020
  26. SEMMLER G, Binter T, Kozbial K, Schwabl P, et al
    Non-invasive risk stratification after HCV-eradication in patients with advanced chronic liver disease.
    Hepatology. 2020 Jul 13. doi: 10.1002/hep.31462.
    >> Share

  27. THAN NN, Cataluna JG, Majumdar A
    Acute confusion post liver transplantation: HE or not HE, that is the question.
    Hepatology. 2020 Jul 6. doi: 10.1002/hep.31452.
    >> Share

    May 2020
  28. NAZZAL M, Sur S, Steele R, Khatun M, et al
    Establishment of a PDX tumor from Hepatitis C Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy.
    Hepatology. 2020 May 1. doi: 10.1002/hep.31298.
    >> Share

    April 2020
  29. MELE D, Oliviero B, Mantovani S, Ludovisi S, et al
    Adaptive Natural Killer Cell Functional Recovery in Hepatitis C Virus Cured Patients.
    Hepatology. 2020 Apr 13. doi: 10.1002/hep.31273.
    >> Share

    February 2020
  30. JUNGER H, Knoppke B, Weigand K, Evert K, et al
    Living donor liver transplantation from hepatitis C-infected donor to hepatitis C-infected recipient.
    Hepatology. 2020 Feb 17. doi: 10.1002/hep.31185.
    >> Share

  31. ROINGEARD P, Beaumont E
    Hepatitis C vaccine: 10 good reasons for continuing.
    Hepatology. 2020 Feb 15. doi: 10.1002/hep.31182.
    >> Share

  32. HARTNELL F, Esposito I, Swadling L, Brown A, et al
    Characterising HCV specific CD4+ T-cells following viral-vectored vaccination, directly acting anti-virals and spontaneous viral cure.
    Hepatology. 2020 Feb 3. doi: 10.1002/hep.31160.
    >> Share

    January 2020
  33. DOS SANTOS MARCON P, de Mattos AZ, Alves de Mattos A
    Letter to the editor: Co-infection of human immunodeficiency virus with hepatitis C virus: a change of paradigm.
    Hepatology. 2020 Jan 21. doi: 10.1002/hep.31123.
    >> Share

  34. ANGELIDAKIS G, Krishnan S, Cabrera NL, Jiang Y, et al
    Virologic Impact of Radiotherapy in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma.
    Hepatology. 2020 Jan 16. doi: 10.1002/hep.31114.
    >> Share

    December 2019
  35. GHANY MG, Marks KM, Morgan TR, Wyles DL, et al
    Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
    Hepatology. 2019 Dec 9. doi: 10.1002/hep.31060.
    >> Share

  36. PROESCHOLD-BELL RJ, Evon DM, Yao J, Niedzwiecki D, et al
    A randomized controlled trial of an integrated alcohol reduction intervention in patients with hepatitis C infection.
    Hepatology. 2019 Dec 5. doi: 10.1002/hep.31058.
    >> Share

    October 2019
  37. KAPILA N, Menon KVN, Al-Khalloufi K, Vanatta JM, et al
    HCV NAT positive solid organ allografts transplanted into HCV negative recipients: A real-world experience.
    Hepatology. 2019 Oct 28. doi: 10.1002/hep.31011.
    >> Share

  38. MARTINELLO M, Orkin C, Cooke G, Bhagani S, et al
    Short duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with recent HCV infection.
    Hepatology. 2019 Oct 24. doi: 10.1002/hep.31003.
    >> Share

  39. DANG H, Yeo YH, Yasuda S, Huang CF, et al
    Cure with Interferon Free DAA is Associated with Increased Survival in Patients with HCV related HCC from both East and West.
    Hepatology. 2019 Oct 14. doi: 10.1002/hep.30988.
    >> Share

    September 2019
  40. LEVITSKY J, Asrani SK, Klintmalm G, Schiano T, et al
    Discovery and validation of a biomarker model (preserve) predictive of renal outcomes after liver transplantation.
    Hepatology. 2019 Sep 11. doi: 10.1002/hep.30939.
    >> Share

  41. VERNA EC, Tsapepas D, Emond JC, Brown RS Jr, et al
    Utilization of HCV-Viremic Organs for HCV Negative Recipients: Is Practice Speeding Past the Evidence?
    Hepatology. 2019 Sep 10. doi: 10.1002/hep.30933.
    >> Share

    August 2019
  42. BARRE T, Protopopescu C, Bani-Sadr F, Piroth L, et al
    Elevated fatty liver index as a risk factor for all-cause mortality in HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort study).
    Hepatology. 2019 Aug 29. doi: 10.1002/hep.30914.
    >> Share

  43. JOHIRA Y, Hatooka H, Mori N, Fukuhara T, et al
    Regression of idiopathic thrombocytopenic purpura in a patient with eradication of hepatitis C virus by direct-acting antivirals.
    Hepatology. 2019 Aug 20. doi: 10.1002/hep.30900.
    >> Share

  44. PATRA T, Meyer K, Ray RB, Ray R, et al
    Hepatitis C virus mediated inhibition of miR-181c activates ATM signaling and promotes hepatocyte growth.
    Hepatology. 2019 Aug 10. doi: 10.1002/hep.30893.
    >> Share

  45. ATCHESON E, Li W, Bliss CM, Chinnakannan S, et al
    Use of an outbred rat hepacivirus challenge model for design and evaluation of efficacy of different immunisation strategies for HCV.
    Hepatology. 2019 Aug 10. doi: 10.1002/hep.30894.
    >> Share

    July 2019
  46. MANDORFER M, Kozbial K, Schwabl P, Chromy D, et al
    Changes in HVPG predict hepatic decompensation in patients who achieved SVR to IFN-free therapy.
    Hepatology. 2019 Jul 31. doi: 10.1002/hep.30885.
    >> Share

    June 2019
  47. JONAS MM, Squires RH, Rhee SM, Lin CW, et al
    Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents with Chronic HCV: Part 1 of the DORA Study.
    Hepatology. 2019 Jun 29. doi: 10.1002/hep.30840.
    >> Share

  48. ROSENTHAL P, Schwarz KB, Gonzalez-Peralta RP, Lin CH, et al
    Sofosbuvir and Ribavirin Therapy for Children 3 to <12 Years Old With Hepatitis C Virus Genotype 2 or 3 Infection.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30821.
    >> Share

  49. KANWAL F, Kramer JR, Asch SM, Cao Y, et al
    Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30823.
    >> Share

  50. SCHWARZ KB, Rosenthal P, Murray KF, Honegger JR, et al
    Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30830.
    >> Share

    May 2019
  51. OREKONDY N, Cafardi J, Kushner T, Reau N, et al
    HCV in Women and Pregnancy.
    Hepatology. 2019 May 28. doi: 10.1002/hep.30791.
    >> Share

  52. WRENSCH F, Ligat G, Heydmann L, Schuster C, et al
    IFITMs mediate viral evasion in acute and chronic hepatitis C virus infection.
    Hepatology. 2019 May 7. doi: 10.1002/hep.30699.
    >> Share

    April 2019
  53. JENSEN SB, Fahnoe U, Pham LV, Serre S, et al
    Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.
    Hepatology. 2019 Apr 9. doi: 10.1002/hep.30647.
    >> Share

  54. JAIN MK, Rich NE, Ahn C, Turner BJ, et al
    Evaluation of a multifaceted intervention to reduce health disparities in hepatitis C screening: a pre-post analysis.
    Hepatology. 2019 Apr 4. doi: 10.1002/hep.30638.
    >> Share

  55. BAKR O, Gelberg L, Seragaki S, Youn S, et al
    Treating Hepatitis C in the Homeless at the Greater Los Angeles Veterans Affairs.
    Hepatology. 2019 Apr 4. doi: 10.1002/hep.30643.
    >> Share

  56. HOFMEISTER MG, Edlin BR, Rosenberg ES, Rosenthal EM, et al
    Reply to HCV prevalence estimates among incarcerated persons (Letter to the Editor regarding HEP-18-1268.R1).
    Hepatology. 2019 Apr 4. doi: 10.1002/hep.30635.
    >> Share

  57. SPAULDING AC, Graham CS, Akiyama MJ, Chhatwal J, et al
    HCV prevalence estimates among incarcerated persons.
    Hepatology. 2019 Apr 2. doi: 10.1002/hep.30636.
    >> Share

    February 2019
  58. WANG R, Zhu P
    Tuberculosis and anti-tuberculosis treatments cannot be ignored when evaluating cirrhotic patients co-infected with HIV or not.
    Hepatology. 2019 Feb 25. doi: 10.1002/hep.30582.
    >> Share

    January 2019
  59. COTTER TG, Paul S, Sandikci B, Couri T, et al
    Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of HCV-Viremic Donors into HCV-Negative Recipients.
    Hepatology. 2019 Jan 31. doi: 10.1002/hep.30540.
    >> Share

  60. ZEUZEM S, Bourgeois S, Greenbloom S, Buti M, et al
    JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-infected Patients without Cirrhosis: OMEGA-1.
    Hepatology. 2019 Jan 28. doi: 10.1002/hep.30527.
    >> Share

  61. COYLE C, Moorman AC, Bartholomew T, Klein G, et al
    The HCV care continuum: linkage to HCV care and treatment among patients at an urban health network, Philadelphia, PA.
    Hepatology. 2019 Jan 11. doi: 10.1002/hep.30501.
    >> Share

    December 2018
  62. SALMON-CERON D, Nahon P, Layese R, Bourcier V, et al
    HIV/HCV co-infected cirrhotic patients are no longer at higher risk for HCC or end-stage liver disease as compared to HCV mono-infected patients.
    Hepatology. 2018 Dec 19. doi: 10.1002/hep.30400.
    >> Share

  63. WU J, Zhou Y, Fu X, Deng M, et al
    The burden of chronic hepatitis C in China from 2004 to 2050: an individual-based modeling study.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30476.
    >> Share

    November 2018
  64. HOFMEISTER MG, Rosenthal EM, Barker LK, Rosenberg ES, et al
    Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016.
    Hepatology. 2018 Nov 6. doi: 10.1002/hep.30297.
    >> Share

  65. DAVIS C, Mgomella GS, Filipe ADS, Frost EH, et al
    New highly diverse hepatitis C strains detected in sub-Saharan Africa have unknown susceptibility to direct-acting antiviral treatments.
    Hepatology. 2018 Nov 2. doi: 10.1002/hep.30342.
    >> Share

    October 2018
  66. PARK H, Wang W, Henry L, Nelson DR, et al
    Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C patients in the U.S.
    Hepatology. 2018 Oct 5. doi: 10.1002/hep.30303.
    >> Share

    September 2018
  67. BOESECKE C, Rockstroh JK
    (Mid)West Side Story: Acute Hepatitis C Virus Infection and the Opioid Epidemic in the United States.
    Hepatology. 2018 Sep 25. doi: 10.1002/hep.30290.
    >> Share

  68. LIU X, Duan X, Holmes JA, Li W, et al
    A novel lncRNA regulates HCV infection through IFI6.
    Hepatology. 2018 Sep 10. doi: 10.1002/hep.30266.
    >> Share

  69. KAO WY, Su CW, Tan EC, Lee PC, et al
    Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B or C.
    Hepatology. 2018 Sep 2. doi: 10.1002/hep.30247.
    >> Share

  70. SERPER M
    Direct acting antivirals for patients without advanced liver disease: All for treatment and treatment for all?
    Hepatology. 2018;68:804-806.
    >> Share

  71. ZUCKER SD, Fried MW
    Parsing the guidelines on guidelines: Balancing sensibility and conflict of interest.
    Hepatology. 2018;68:798-800.
    >> Share

  72. BACKUS LI, Belperio PS, Shahoumian TA, Mole LA, et al
    Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease.
    Hepatology. 2018;68:827-838.
    >> Share

    August 2018
  73. FOURATI S, Rodriguez C, Hezode C, Soulier A, et al
    Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r.
    Hepatology. 2018 Aug 19. doi: 10.1002/hep.30225.
    >> Share

  74. RAY RB, Ray R
    Hepatitis C virus manipulates humans as its favorite host for long term relationship.
    Hepatology. 2018 Aug 13. doi: 10.1002/hep.30214.
    >> Share

  75. MURRAY KF, Balistreri WF, Bansal S, Whitworth S, et al
    Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30123.
    >> Share

  76. GANE EJ, Stedman CA, Schwabe C, Vijgen L, et al
    Short Duration AL-335, Odalasvir, With/Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30126.
    >> Share

  77. REFOLO G, Ciccosanti F, Di Rienzo M, Perdomo AB, et al
    Negative regulation of MAVS-mediated antiviral signaling by the mitochondrial protein LRPPRC during HCV infection.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30149.
    >> Share

  78. HUSSAINI T, Krajden M, Mitchell RA, Yoshida EM, et al
    Transplanting Hepatitis C seropositive, nucleic acid test negative donor organs into hepatitis C negative recipients.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30121.
    >> Share

    July 2018
  79. GOLDEN-MASON L, Rosen HR
    Revisiting the Paradox of ISG expression as a predictor of HCV treatment response, a decade later.
    Hepatology. 2018 Jul 28. doi: 10.1002/hep.30195.
    >> Share

  80. JAIN MK, Thamer M, Therapondos G, Shiffman ML, et al
    Has Access to HCV Therapy Changed for Patients with Mental Health or Substance Use Disorders in the DAA Period?
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30171.
    >> Share

  81. TUCCI F, Calbi V, Barzaghi F, Migliavacca M, et al
    Successful treatment with Harvoni((R)) in an ADA-SCID infant with HCV infection allowed gene therapy with Strimvelis((R)).
    Hepatology. 2018 Jul 16. doi: 10.1002/hep.30160.
    >> Share

    June 2018
    Transplantation of Livers from Viremic HCV Positive Donors into HCV Negative Recipients.
    Hepatology. 2018 Jun 11. doi: 10.1002/hep.30106.
    >> Share

    May 2018
  83. COURI T, Gupta T, Weyer G, Aronsohn A, et al
    Pay It Forward: Building Capacity to Treat Hepatitis C by Training Our Own Residents.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30101.
    >> Share

  84. SALAM KA, Wang RY, Grandinetti T, De Giorgi V, et al
    Binding of Free and Immune Complex-Associated Hepatitis C Virus to Erythrocytes Is Mediated by the Complement System.
    Hepatology. 2018 May 9. doi: 10.1002/hep.30087.
    >> Share

  85. ZHANG H, Zhang C, Tang H, Gao S, et al
    CD2-associated Protein Contributes to Hepatitis C Virus Propagation and Steatosis by Disrupting Insulin Signaling.
    Hepatology. 2018 May 5. doi: 10.1002/hep.30073.
    >> Share

    April 2018
  86. ALAO H, Cam M, Keembiyehetty C, Zhang F, et al
    Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During DAA Therapy.
    Hepatology. 2018 Apr 27. doi: 10.1002/hep.29921.
    >> Share

  87. YANG JD, Gores GJ
    Does Cirrhosis Associated with Well Controlled Viral Hepatitis Confer a Risk for Extrahepatic Cancer?
    Hepatology. 2018 Apr 26. doi: 10.1002/hep.30063.
    >> Share

  88. CHOLANKERIL G, Gadiparthi C, Kim D, Ahmed A, et al
    Expanding Donor Pool for Liver Transplantation by Utilizing Hepatitis C Virus-Infected Donors for Uninfected Recipients.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30043.
    >> Share

    Hepatitis C in Patients with Renal Disease: A Deeper Dive into the KDIGO Guideline.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30047.
    >> Share

  90. REAU N, Kwo PY, Rhee S, Brown RS Jr., et al
    Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30046.
    >> Share

  91. CHHATWAL J, Bethea ED, Samur S, Chung RT, et al
    Reply to Expanding Donor Pool for Liver Transplantation by Utilizing Hepatitis C Virus-Infected Donors for Uninfected Recipients.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30042.
    >> Share

  92. KWONG AJ, Kim WR, Flemming JA
    De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30045.
    >> Share

  93. ALLAIRE M, Nahon P, Layese R, Bourcier V, et al
    Extra hepatic cancers are the leading cause of death in cirrhotic patients achieving HBV control or HCV eradication.
    Hepatology. 2018 Apr 16. doi: 10.1002/hep.30034.
    >> Share

  94. WENDUM D, Layese R, Ganne-Carrie N, Bourcier V, et al
    Influence of progenitor-derived regeneration markers on HCV-related cirrhosis outcome (ANRS CO12 CirVir cohort).
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29927.
    >> Share

  95. HOUSSEL-DEBRY P, Coilly A, Fougerou-Leurent C, Jezequel C, et al
    12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation.
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29918.
    >> Share

    March 2018
  96. FAILLACI F, Marzi L, Critelli R, Milosa F, et al
    Liver Angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after HCV direct-acting antivirals.
    Hepatology. 2018 Mar 31. doi: 10.1002/hep.29911.
    >> Share

  97. RAMAMURTHY N, Marchi E, Ansari MA, Pedergnana V, et al
    Impact of IFNL4 genotype on Interferon-stimulated Gene Expression during DAA therapy for Hepatitis C.
    Hepatology. 2018 Mar 13. doi: 10.1002/hep.29877.
    >> Share

    February 2018
  98. HUANG AC, Mehta N, Dodge JL, Yao FY, et al
    Direct-acting Antivirals Do Not Increase the Risk of Hepatocellular Carcinoma Recurrence after Local-Regional Therapy or Liver Transplant Waitlist Dropout.
    Hepatology. 2018 Feb 24. doi: 10.1002/hep.29855.
    >> Share

  99. FOSTER GR, Agarwal K, Cramp ME, Moreea S, et al
    Elbasvir/Grazoprevir and Sofosbuvir for HCV Genotype 3 Infection With Compensated Cirrhosis: A Randomized Trial.
    Hepatology. 2018 Feb 23. doi: 10.1002/hep.29852.
    >> Share

  100. KWON YC, Meyer K, Peng G, Chatterjee S, et al
    Hepatitis C virus E2 envelope glycoprotein induces an immunoregulatory phenotype in macrophages.
    Hepatology. 2018 Feb 14. doi: 10.1002/hep.29843.
    >> Share

  101. DOI A, Hikita H, Sakamori R, Tahata Y, et al
    NS5A-P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection.
    Hepatology. 2018 Feb 9. doi: 10.1002/hep.29836.
    >> Share

  102. SMITH D, Magri A, Bonsall D, Ip CL, et al
    Resistance analysis of genotype 3 HCV indicates subtypes inherently resistant to NS5A inhibitors.
    Hepatology. 2018 Feb 9. doi: 10.1002/hep.29837.
    >> Share

    January 2018
  103. BERENGUER J, Gil-Martin A, Jarrin I, Moreno A, et al
    All-oral DAA therapy against HCV in HIV/HCV-coinfected subjects in real-world practice: Madrid-CoRe Findings.
    Hepatology. 2018 Jan 29. doi: 10.1002/hep.29814.
    >> Share

  104. BETHEA E, Chen Q, Hur C, Chung RT, et al
    Response to Treatment of Acute HCV Cost-Effective but at What Price?
    Hepatology. 2018 Jan 5. doi: 10.1002/hep.29770.
    >> Share

  105. CONGLY SE, Lee SS
    Treatment of Acute HCV Cost-Effective but at What Price?
    Hepatology. 2018 Jan 5. doi: 10.1002/hep.29771.
    >> Share

  106. HERRMANN E, de Ledinghen V, Cassinotto C, Chu WC, et al
    Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis.
    Hepatology. 2018;67:260-272.
    >> Share

    December 2017
  107. GRAKOUI A, Walker CM
    Of mice, rats and men: Small animal model of hepatitis C virus infection.
    Hepatology. 2017 Dec 27. doi: 10.1002/hep.29765.
    >> Share

    Regression of HCV cirrhosis: Time will tell.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29720.
    >> Share

  109. CHHATWAL J, Samur S, Bethea ED, Ayer T, et al
    Transplanting HCV-positive livers into HCV-negative patients with preemptive antiviral treatment: A modeling study.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29723.
    >> Share

  110. BARI K, Luckett K, Kaiser T, Diwan T, et al
    Hepatitis C Transmission from Seropositive, Non-Viremic Donors to Non-Hepatitis C Liver Transplant Recipients.
    Hepatology. 2017 Dec 2. doi: 10.1002/hep.29704.
    >> Share

  111. LI DK, Ren Y, Fierer DS, Rutledge S, et al
    The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.
    Hepatology. 2017 Dec 2. doi: 10.1002/hep.29707.
    >> Share

  112. SORIA A, Lapadula G, Fabbiani M, Gori A, et al
    Lower effectiveness of hepatitis C antiviral treatment in patients with hepatocellular carcinoma: Is active tumor the clue?
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29700.
    >> Share

  113. JI F, Yeo YH, Wei MT, Wei B, et al
    Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment: does direct-acting antiviral regimens matter?
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29701.
    >> Share

  114. HARRINGTON PR, Komatsu TE, Deming DJ, Donaldson EF, et al
    Impact of Hepatitis C Virus Polymorphisms on Direct-Acting Antiviral Treatment Efficacy: Regulatory Analyses and Perspectives.
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29693.
    >> Share

    November 2017
  115. SAAB S, Le L, Saggi S, Sundaram V, et al
    Towards the Elimination of Hepatitis C in the United States.
    Hepatology. 2017 Nov 27. doi: 10.1002/hep.29685.
    >> Share

  116. CHANG FM, Wang YP, Lu CL
    Reply: Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29686.
    >> Share

  117. LIN CY
    Statins and risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: Methodological issues.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29687.
    >> Share

  118. POORDAD F, Pol S, Asatryan A, Buti M, et al
    Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1 or 4 and Prior Direct-acting Antiviral Treatment Failure.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29671.
    >> Share

  119. KALAL C, Shukla A, Mohanka R, Vora M, et al
    Sofosbuvir, Peg Interferon & Ribavirin for retreatment of HCV genotype 1b following Sofosbuvir and Ledipasvir failure.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29667.
    >> Share

  120. PARK H, O'Brien TR, Rehermann B
    The role of genetics in hepatic fibrosis amongst HCV patients.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29659.
    >> Share

  121. SIKAVI C, Chen PH, Lee AD, Saab EG, et al
    Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population.
    Hepatology. 2017 Nov 6. doi: 10.1002/hep.29642.
    >> Share

    October 2017
  122. LIU J
    Hepatitis B reactivation in chronic hepatitis C patients treated with interferon or pan-oral direct-acting antivirals.
    Hepatology. 2017 Oct 28. doi: 10.1002/hep.29620.
    >> Share

  123. STRUBLE K, Chan-Tack K, Qi K, Naeger LK, et al
    Benefit-Risk Assessment for Sofosbuvir/Velpatasvir/Voxilaprevir Based on Patient Population and HCV genotype: FDA's Evaluation.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29601.
    >> Share

  124. BETHEA E, Chen Q, Hur C, Chung RT, et al
    Should we treat acute hepatitis C? A decision and cost-effectiveness analysis.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29611.
    >> Share

    The Efficacy of New Anti-Viral Regimens for Hepatitis C Infection: Evidence from A Systematic Review.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29580.
    >> Share

  126. GONZALEZ SA, Trotter JF
    The Rise of the Opioid Epidemic and Hepatitis C Positive Organs: A New Era in Liver Transplantation.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29572.
    >> Share

    September 2017
  127. MAUGE L, Pavie J, Batisse D, Darnige L, et al
    Acquired hemophilia A resolution in an HCV/HIV coinfected patient with cure of hepatitis C by direct antiviral agents.
    Hepatology. 2017 Sep 28. doi: 10.1002/hep.29560.
    >> Share

  128. CHTIOUI H
    OATP1B1 and DAA treatment for hepatitis C in patients with hepatocellular carcinoma.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29556.
    >> Share

  129. AHMED A, Beckerman R, Younossi ZM
    Equitable Access to All-Oral Direct-Acting Antiviral Therapy is a Mandatory Step to Achieve Global Hepatitis C Virus Eradication.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29555.
    >> Share

  130. MAURO E, Crespo G, Montironi C, Londono MC, et al
    Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after SVR in recurrent hepatitis C.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29557.
    >> Share

  131. LIU X, Elmofti Y, Kulaga C, Gisi B, et al
    Societal perspectives' analysis for evaluating direct-acting antivirals affordability while awaiting liver transplant.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29558.
    >> Share

  132. YARTEL AK, Rein DB, Ann Brown K, Krauskopf K, et al
    Hepatitis C Virus Testing for Case Identification in Persons Born during 1945-1965: Results from Three Randomized Controlled Trials.
    Hepatology. 2017 Sep 23. doi: 10.1002/hep.29548.
    >> Share

  133. WYLES D, Poordad F, Wang S, Alric L, et al
    Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial.
    Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541.
    >> Share

  134. VIONNET J, Pascual M, Testoni B, Combet C, et al
    Late hepatitis B reactivation following DAA-based treatment of recurrent hepatitis C in an anti-HBc-positive liver transplant recipient.
    Hepatology. 2017 Sep 16. doi: 10.1002/hep.29528.
    >> Share

  135. LEE MH, Huang YH, Chen HY, Khor CS, et al
    Human Leukocyte Antigen Variants and Risk of Hepatocellular Carcinoma Modified by HCV Genotypes: A Genome-wide Association Study.
    Hepatology. 2017 Sep 16. doi: 10.1002/hep.29531.
    >> Share

  136. PARK H, Chen C, Wang W, Henry L, et al
    Chronic Hepatitis C Increases the Risk of Chronic Kidney Disease (CKD) while Effective HCV Treatment Decreases the Incidence of CKD.
    Hepatology. 2017 Sep 5. doi: 10.1002/hep.29505.
    >> Share

  137. TOYODA H, Chayama K, Suzuki F, Sato K, et al
    Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients with Chronic Genotype 2 Hepatitis C Virus Infection.
    Hepatology. 2017 Sep 2. doi: 10.1002/hep.29510.
    >> Share

    August 2017
  138. TRIVEDI S, Murthy S, Sharma H, Hartlage AS, et al
    Viral persistence, liver disease and host response in Hepatitis C-like virus rat model.
    Hepatology. 2017 Aug 31. doi: 10.1002/hep.29494.
    >> Share

  139. MATTINGLY TJ 2ND, Perfetto EM, Johnson S
    Engaging hepatitis C infected patients in cost-effectiveness analyses: A literature review.
    Hepatology. 2017 Aug 23. doi: 10.1002/hep.29482.
    >> Share

  140. INNES H, McAuley A, Alavi M, Valerio H, et al
    The contribution of health risk behaviours to excess mortality in American adults with chronic hepatitis C: A population cohort-study.
    Hepatology. 2017 Aug 4. doi: 10.1002/hep.29419.
    >> Share

  141. KRISS M, Burchill M
    HCV and non-hepatic malignancy: Is pre-emptive DAA therapy indicated prior to treatment?
    Hepatology. 2017 Aug 2. doi: 10.1002/hep.29414.
    >> Share

    July 2017
  142. COBB DA, Golden-Mason L, Rosen HR, Hahn YS, et al
    Hepatocyte-derived exosomes promote T follicular regulatory cell expansion during HCV infection.
    Hepatology. 2017 Jul 27. doi: 10.1002/hep.29409.
    >> Share

  143. KONDILI LA, Romano F, Rolli FR, Ruggeri M, et al
    Modelling cost-effectiveness and health gains of a "universal" vs. "prioritized" HCV treatment policy in a real-life cohort.
    Hepatology. 2017 Jul 24. doi: 10.1002/hep.29399.
    >> Share

  144. KONERMAN MA, Thomson M, Gray K, Moore M, et al
    Impact of an Electronic Health Record Alert in Primary Care on Increasing Hepatitis C Screening and Curative Treatment for Baby Boomers.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29362.
    >> Share

  145. PERSICO M, Aglitti A, Caruso R, De Renzo A, et al
    Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29364.
    >> Share

  146. ROSEN HR, Ghany M, Chung R, Lok A, et al
    NAM 2017 Report: A National Plan To Eliminate Hepatitis B and C In the United States By 2030 And The AASLD's Response.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29361.
    >> Share

  147. LOK AS, Chung RT, Vargas HE, Kim AY, et al
    Comments on Cochrane Review on Direct-Acting Antivirals for Hepatitis C.
    Hepatology. 2017 Jul 16. doi: 10.1002/hep.29366.
    >> Share

  148. WYLES D, Wedemeyer H, Ben-Ari Z, Gane EJ, et al
    Grazoprevir, Ruzasvir, and Uprifosbuvir for HCV After NS5A Treatment Failure.
    Hepatology. 2017 Jul 7. doi: 10.1002/hep.29358.
    >> Share

    June 2017
  149. SASAKI R, Devhare P, Ray RB, Ray R, et al
    Hepatitis C virus induced tumor initiating cancer stem-like cells activate stromal fibroblasts in xenograft tumor model.
    Hepatology. 2017 Jun 30. doi: 10.1002/hep.29346.
    >> Share

  150. TORRES HA, Hosry J, Mahale P, Economides MP, et al
    Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study.
    Hepatology. 2017 Jun 27. doi: 10.1002/hep.29344.
    >> Share

  151. SISE M
    Kidney transplant recipients with Hepatitis C virus experienced 100% SVR12 rate when treated with sofosbuvir-ledipasvir.
    Hepatology. 2017 Jun 26. doi: 10.1002/hep.29339.
    >> Share

  152. CHIDA T, Ito M, Nakashima K, Kanegae Y, et al
    Critical role of CREBH-mediated induction of TGF-beta2 by HCV infection in fibrogenic responses in hepatic stellate cells.
    Hepatology. 2017 Jun 16. doi: 10.1002/hep.29319.
    >> Share

  153. FALADE-NWULIA O, Sutcliffe C, Moon J, Chander G, et al
    High Hepatitis C cure rates among black and non-black HIV-infected adults in an urban center.
    Hepatology. 2017 Jun 13. doi: 10.1002/hep.29308.
    >> Share

  154. CHHATWAL J, Samur S, Bethea E, Chung RT, et al
    Response to Optimal Timing for Hepatitis C Antiviral Therapy in the Peri-Transplant Period?
    Hepatology. 2017 Jun 6. doi: 10.1002/hep.29299.
    >> Share

  155. CHOLANKERIL G, Wong RJ, Kim D, Ahmed A, et al
    Optimal Timing for Hepatitis C Antiviral Therapy in the Peri-Transplant Period?
    Hepatology. 2017 Jun 6. doi: 10.1002/hep.29300.
    >> Share

    May 2017
  156. WIRTH S, Rosenthal P, Gonzalez-Peralta RP, Jonas MM, et al
    Sofosbuvir and Ribavirin in Adolescents 12 to 17 Years Old With Hepatitis C Virus Genotype 2 or 3 Infection.
    Hepatology. 2017 May 22. doi: 10.1002/hep.29278.
    >> Share

  157. SAXENA V, Khungar V, Verna EC, Levitsky J, et al
    Safety and Efficacy of Current DAA Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Results from the HCV-TARGET Study.
    Hepatology. 2017 May 15. doi: 10.1002/hep.29258.
    >> Share

  158. GANE EJ, Shiffman ML, Etzkorn K, Morelli G, et al
    Sofosbuvir-velpatasvir with ribavirin for 24 weeks in HCV patients previously treated with a direct-acting antiviral regimen.
    Hepatology. 2017 May 12. doi: 10.1002/hep.29256.
    >> Share

    April 2017
  159. PEMBROKE T, Sebastiani G
    Hepatic steatosis, hepatitis C and human immunodeficiency viruses: A complex interplay.
    Hepatology. 2017 Apr 19. doi: 10.1002/hep.29218.
    >> Share

  160. GUO X, Wang S, Qiu ZG, Dou YL, et al
    Efficient replication of blood borne Hepatitis C Virus in human fetal liver stem cells.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29211.
    >> Share

  161. ONO A, Goossens N, Finn RS, Schmidt WN, et al
    Persisting risk of hepatocellular carcinoma after HCV cure monitored by a liver transcriptome signature.
    Hepatology. 2017 Apr 8. doi: 10.1002/hep.29203.
    >> Share

  162. MERLI M, Frigeni M, Gotti M, Grossi P, et al
    Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas.
    Hepatology. 2017 Apr 5. doi: 10.1002/hep.29198.
    >> Share

  163. LAI TS, Lee MH, Yang HI, You SL, et al
    Hepatitis C Viral Load, Genotype, and Increased Risk of Developing End-stage Renal Disease: REVEAL-HCV Study.
    Hepatology. 2017 Apr 2. doi: 10.1002/hep.29192.
    >> Share

    March 2017
    HBV Reactivation During DAA Treatment of Chronic Hepatitis C: A Hidden Danger of an Otherwise Major Success Story.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29185.
    >> Share

  165. SORIA A, Fabbiani M, Lapadula G, Gori A, et al
    Unexpected viral relapses in HCV-infected patients diagnosed with hepatocellular carcinoma during treatment with DAAs.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29181.
    >> Share

  166. KIM SJ, Jang JY, Kim EJ, Cho EK, et al
    Ginsenoside Rg3 Restores Hepatitis C Virus-Induced Aberrant Mitochondrial Dynamics and Inhibits Virus Propagation.
    Hepatology. 2017 Mar 22. doi: 10.1002/hep.29177.
    >> Share

  167. CHANG FM, Wang YP, Lang HC, Tsai CF, et al
    Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: A population-based study.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29172.
    >> Share

  168. SURAWEERA D, Saab S
    Hepatitis C Treatment Threshold in Patients with Decompensated Liver Disease.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29175.
    >> Share

  169. SASAKI R, Devhare PB, Steele R, Ray R, et al
    Hepatitis C virus induced CCL5 secretion from macrophages activates hepatic stellate cells.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29170.
    >> Share

  170. STELMA F, van der Ree MH, Sinnige MJ, Brown A, et al
    Immune phenotype and function of NK and T cells in chronic hepatitis C patients who received a single dose of anti-miR-122, RG-101.
    Hepatology. 2017 Mar 11. doi: 10.1002/hep.29148.
    >> Share

  171. HEZODE C, Colombo M, Bourliere M, Spengler U, et al
    Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.
    Hepatology. 2017 Mar 3. doi: 10.1002/hep.29139.
    >> Share

  172. AHMED A, Gonzalez SA, Cholankeril G, Perumpail RB, et al
    Treatment of Patients Waitlisted for Liver Transplant with an All-Oral DAAs is a Cost-Effective Treatment Strategy in the United States.
    Hepatology. 2017 Mar 3. doi: 10.1002/hep.29137.
    >> Share

    February 2017
  173. BELPERIO PS, Shahoumian TA, Mole LA, Backus LI, et al
    Evaluation of Hepatitis B Reactivation among 62,920 Veterans treated with Oral Hepatitis C Antivirals.
    Hepatology. 2017 Feb 27. doi: 10.1002/hep.29135.
    >> Share

  174. YAN F, Wang Y, Zhang W, Chang M, et al
    Human ES Cell-derived Hepatoblasts are an Optimal Lineage Stage for HCV Infection.
    Hepatology. 2017 Feb 25. doi: 10.1002/hep.29134.
    >> Share

  175. LAWITZ E, Poordad F, Wells J, Hyland RH, et al
    Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in DAA-experienced patients with genotype 1 HCV.
    Hepatology. 2017 Feb 21. doi: 10.1002/hep.29130.
    >> Share

  176. HOGAN JJ, Lim MA, Palmer MB, Bloom RD, et al
    Development of proteinuria and focal segmental glomerulosclerosis during direct acting antiviral therapy for hepatitis C virus infection (HEP-16-2474.R1).
    Hepatology. 2017 Feb 17. doi: 10.1002/hep.29125.
    >> Share

  177. SABERI B, Dadabhai AS, Durand CM, Philosophe B, et al
    Challenges in Treatment of Hepatitis C among Patients with Hepatocellular Carcinoma.
    Hepatology. 2017 Feb 17. doi: 10.1002/hep.29126.
    >> Share

  178. BRUDEN DJ, McMahon BJ, Townshend-Bulson L, Gounder P, et al
    Risk of End Stage Liver Disease, Hepatocellular Carcinoma and Liver-Related Death By Fibrosis Stage in the Hepatitis C Alaska Cohort.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29115.
    >> Share

  179. CHEN G, Wang C, Chen J, Ji D, et al
    Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29109.
    >> Share

  180. DENOLLY S, Cosset FL
    A master regulator of tight junctions involved in hepatitis C virus entry and pathogenesis.
    Hepatology. 2017 Feb 8. doi: 10.1002/hep.29066.
    >> Share

  181. FERNANDEZ CARRILLO C, Lens S, Llop E, Pascasio JM, et al
    Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of MELD: Analysis of data from the Hepa-C registry.
    Hepatology. 2017 Feb 7. doi: 10.1002/hep.29097.
    >> Share

  182. CARTER L, Aronsohn A
    Overcoming Injustice: A Roadmap to Improve Access to HCV Therapy for Our Medicaid Patients.
    Hepatology. 2017 Feb 4. doi: 10.1002/hep.29095.
    >> Share

  183. OLIVEIRA C, Fournier C, Descamps V, Morel V, et al
    Apolipoprotein(a) Inhibits Hepatitis C Virus Entry Through Interaction With Infectious Particles.
    Hepatology. 2017 Feb 2. doi: 10.1002/hep.29096.
    >> Share

  184. TEDESCO D, Thapa M, Gumber S, Elrod EJ, et al
    CD4+ Foxp3+ T cells promote aberrant immunoglobulin G production and maintain CD8+ T-cell suppression during chronic liver disease.
    Hepatology. 2017;65:661-677.
    >> Share

    January 2017
  185. POORDAD F, Felizarta F, Asatryan A, Sulkowski MS, et al
    Glecaprevir and Pibrentasvir for 12 Weeks for HCV Genotype 1 Infection and Prior Direct-acting Antiviral Treatment.
    Hepatology. 2017 Jan 27. doi: 10.1002/hep.29081.
    >> Share

  186. BERENGUER J, Rodriguez-Castellano E, Carrero A, Von Wichmann MA, et al
    Eradication of HCV and non-liver-related non-AIDS-related events in HIV/HCV coinfection.
    Hepatology. 2017 Jan 21. doi: 10.1002/hep.29071.
    >> Share

  187. COUSIEN A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, et al
    Reply to "Addressing opioid use disorder in modeling hepatitis C transmission among persons who inject drugs".
    Hepatology. 2017 Jan 21. doi: 10.1002/hep.29069.
    >> Share

  188. SMITH J, Rich J
    Addressing opioid use disorder in modeling hepatitis C transmission among persons who inject drugs.
    Hepatology. 2017 Jan 21. doi: 10.1002/hep.29070.
    >> Share

  189. O'BRIEN TR, Kottilil S, Feld JJ, Morgan TR, et al
    Race or Genetic Makeup for HCV Treatment Decisions?
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29057.
    >> Share

  190. SU F, Ioannou GN
    Reply to: Race or Genetic Makeup for HCV Treatment Decisions?
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29058.
    >> Share

  191. VERNA EC
    The Dynamic Landscape of Liver Transplant in the Era of Effective HCV Therapy.
    Hepatology. 2017 Jan 17. doi: 10.1002/hep.29054.
    >> Share

  192. ARORA P, Basu A, Schmidt ML, Clark GJ, et al
    NS5B Promotes Degradation of the NORE1A Tumor Suppressor to Facilitate Hepatitis C Virus Replication.
    Hepatology. 2017 Jan 16. doi: 10.1002/hep.29049.
    >> Share

  193. HEI L, Zhong J
    LGP2 plays an essential role in HCV infection-induced interferon responses.
    Hepatology. 2017 Jan 16. doi: 10.1002/hep.29050.
    >> Share

    December 2016
  194. KOWDLEY KV, Sundaram V, Jeon CY, Qureshi K, et al
    Eight weeks of Ledipasvir/Sofosbuvir is effective for selected patients with genotype 1 Hepatitis C virus infection.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29005.
    >> Share

  195. VIETHEER P, Boo I, Gu J, McCaffrey K, et al
    The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28989.
    >> Share

  196. BALISTRERI WF, Murray KF, Rosenthal P, Bansal S, et al
    The Safety and Effectiveness of Ledipasvir-Sofosbuvir in Adolescents 12 to 17 Years Old With Hepatitis C Virus Genotype 1 Infection.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28995.
    >> Share

  197. MARTINI S, Salizzoni M, David E, Tandoi F, et al
    Favorable short-term outcome of HCV-positive liver graft with bridging fibrosis: A plea for very early viral eradication.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28978.
    >> Share

  198. PRICE JC, Ma Y, Scherzer R, Korn N, et al
    HIV-infected and Uninfected Adults with Non-Genotype 3 Hepatitis C Virus Have Less Hepatic Steatosis than Adults with Neither Infection.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28968.
    >> Share

  199. ARTEMOVA M, Abdurakhmanov D, Ignatova T, Mukhin N, et al
    Persistent HCV-associated Cryoglobulinemic Vasculitis Following Virus Eradication after Direct-Acting Antivirals Therapy.
    Hepatology. 2016 Dec 10. doi: 10.1002/hep.28981.
    >> Share

    November 2016
  200. LEVY PL, Duponchel S, Eischeid H, Molle J, et al
    Hepatitis C virus infection triggers a tumor-like glutamine metabolism.
    Hepatology. 2016 Nov 18. doi: 10.1002/hep.28949.
    >> Share

  201. CHHATWAL J, Samur S, Kues B, Ayer T, et al
    Optimal Timing of Hepatitis C Treatment for Patients on the Liver Transplant Waiting List.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28926.
    >> Share

  202. NIU Y, Xu M, Slagle BL, Huang H, et al
    Farnesoid X receptor ablation sensitizes mice to hepatitis b virus X protein-induced hepatocarcinogenesis.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28924.
    >> Share

  203. FLEMMING JA, Kim WR, Brosgart CL, Terrault NA, et al
    Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28923.
    >> Share

    October 2016
  204. SU F, Green PK, Berry K, Ioannou GN, et al
    The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28901.
    >> Share

  205. LAWITZ E, Poordad F, Gutierrez JA, Wells JT, et al
    Short-duration Treatment With Elbasvir/Grazoprevir and Sofosbuvir for Hepatitis C: A Randomized Trial.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28877.
    >> Share

  206. BRADY JE, Liffmann DK, Yartel A, Kil N, et al
    Uptake of Hepatitis C Screening, Characteristics of Patients Tested, and Intervention Costs in the BEST-C Study.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28880.
    >> Share

  207. MAROT A, Vandenbulcke H, Knebel JF, Doerig C, et al
    External validation of the nomogram for individualized prediction of HCC occurrence in patients with HCV-related compensated cirrhosis.
    Hepatology. 2016 Oct 13. doi: 10.1002/hep.28865.
    >> Share

    September 2016
  208. KLEPPER A, Eng FJ, Doyle EH, El-Shamy A, et al
    Hepatitis C virus double-stranded RNA is the predominant form in human liver and in interferon-treated cells.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28846.
    >> Share

  209. WANG RY, Bare P, De Giorgi V, Matsuura K, et al
    Preferential Association of Hepatitis C Virus with CD19+ B Cells Is Mediated by Complement System.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28842.
    >> Share

  210. KECK ZY, Wang Y, Lau P, Lund G, et al
    Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute HCV infection.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28850.
    >> Share

  211. ROSEN HR
    "Hep C, where art thou": What are the remaining (fundable) questions in HCV research?
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28848.
    >> Share

  212. NISHIO A, Tatsumi T, Nawa T, Suda T, et al
    CD14+ monocyte-derived Galectin-9 induces NK cell cytotoxicity in chronic hepatitis C.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28847.
    >> Share

  213. MARTINELLO M, Gane E, Hellard M, Sasadeusz J, et al
    Sofosbuvir and ribavirin for six weeks is not effective among people with recent HCV infection: The DARE-C II study.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28844.
    >> Share

  214. HILL LA, Wyles DL
    Emerging complexities with HCV DAA regimens: Less is still way more.
    Hepatology. 2016 Sep 16. doi: 10.1002/hep.28832.
    >> Share

    December 2015
  215. CHO NE, Bang BR, Gurung P, Li M, et al
    Retinoid Regulation of Antiviral Innate Immunity in Hepatocytes.
    Hepatology. 2015 Dec 5. doi: 10.1002/hep.28380.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016